Cinrebafusp alfa Biosimilar – Anti-CD137 fusion protein – Research Grade

Title: Understanding the Structure and

Activity of Cinrebafusp alfa Biosimilar – Anti-CD137 Fusion Protein Introduction

Cinrebafusp alfa is a biosimilar of the anti-CD137 fusion protein, which has shown promising results in cancer immunotherapy. In this article, we will delve into the structure and activity of Cinrebafusp alfa, as well as its potential applications as a therapeutic target in cancer treatment.

Structure of Cinrebafusp alfa

Cinrebafusp alfa is a fusion protein composed of two distinct components – a human IgG1 antibody and a soluble form of the CD137 receptor. The human IgG1 antibody serves as the targeting moiety, while the soluble CD137 receptor acts as the effector molecule. The two components are linked together by a flexible linker, allowing for optimal binding and activation of CD137 receptor.

Activity of Cinrebafusp alfa

The CD137 receptor, also known as 4-1BB, is a member of the tumor necrosis factor receptor superfamily. It is expressed on the surface of activated T cells and natural killer cells, and its activation leads to enhanced T cell proliferation, survival, and cytokine production. Cinrebafusp alfa binds to tumor cells expressing CD137, leading to the activation of the receptor and subsequent immune response against the tumor.

In addition, Cinrebafusp alfa has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This mechanism involves the binding of the Fc region of the human IgG1 antibody to Fc receptors on immune cells, such as natural killer cells, which then target and kill tumor cells expressing CD137.

Potential Applications of Cinrebafusp alfa

Cinrebafusp alfa has shown promising results in preclinical studies as a potential treatment for various types of cancer, including melanoma, breast cancer, and lung cancer. Its unique mechanism of action, targeting the CD137 receptor, makes it a promising therapeutic option for cancers that are resistant to other treatments.

In addition, Cinrebafusp alfa has been shown to have a synergistic effect when combined with other cancer treatments, such as chemotherapy and checkpoint inhibitors. This combination therapy has been shown to enhance the anti-tumor immune response and improve overall treatment outcomes.

Research Grade Cinrebafusp alfa

Cinrebafusp alfa is currently being developed as a research grade product, which is intended for use in preclinical and clinical studies. It is produced using recombinant DNA technology, ensuring high purity and consistency in each batch. This allows for reliable and reproducible results in research studies.

Conclusion

In summary, Cinrebafusp alfa is a biosimilar of the anti-CD137 fusion protein with a unique structure and mechanism of action. Its ability to activate the CD137 receptor and induce ADCC makes it a promising candidate for cancer immunotherapy. Its potential applications in combination with other cancer treatments make it an exciting area of research in the field of oncology. As a research grade product, Cinrebafusp alfa provides a valuable tool for further understanding and developing this promising therapeutic option for cancer treatment.